Jazz Pharma reports strong growth
Jazz Pharmaceuticals reported strong growth in its second quarter last week, as revenues rose due to accelerating sales of sleep drug Xyrem and its new anticoagulant defibrotide. The firm reported revenue of $291.2 million, up almost 40 per cent year on year. Jazz also reported adjusted net profit of $128 million, or $2.05 a share, a figure which was ahead of expectations.
Jazz has updated its guidance for the full year, with revenue now...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
*New subscribers only
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team